Tenax Therapeutics (TENX) Other Accumulated Expenses (2015 - 2024)
Tenax Therapeutics (TENX) posted quarterly Other Accumulated Expenses of $105823.0 for Q3 2024, down 56.9% year-over-year from $245545.0 in Q4 2023, and down 34.1% on a QoQ basis from $160581.0 in Q2 2024.
Tenax Therapeutics (TENX) Other Accumulated Expenses (2015 - 2024) Analysis & Trends
Tenax Therapeutics has reported Other Accumulated Expenses for 10 years, with the latest figure at $105823.0 in Q3 2024.
- Other Accumulated Expenses for Q3 2024 came in at $105823.0, down 56.9% year-over-year; the trailing twelve-month figure through Sep 2024 was $105823.0 (down 56.9% YoY), and the FY2023 annual result was $236878.0, down 3.47% from the prior year.
- Other Accumulated Expenses eased to $105823.0 in Q3 2024, from $160581.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $503023.0 in Q1 2020 and troughed at $84595.0 in Q1 2021.
- A 5-year average of $223434.9 and a median of $238206.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The widest annual swing landed in 2020, when Other Accumulated Expenses plunged 86.03%; it then soared 208.98% in 2022.
- A 5-year view of Other Accumulated Expenses shows it stood at $319608.0 in 2020, then plunged by 62.96% to $118372.0 in 2021, then jumped by 107.3% to $245391.0 in 2022, then fell by 3.47% to $236878.0 in 2023, then sank by 55.33% to $105823.0 in 2024.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $105823.0 in Q3 2024, $160581.0 in Q2 2024, and $253517.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 105,823.00 |
| Jun 30, 2024 | 160,581.00 |
| Mar 31, 2024 | 253,517.00 |
| Dec 31, 2023 | 236,878.00 |
| Sep 30, 2023 | 245,545.00 |
| Jun 30, 2023 | 230,000.00 |
| Mar 31, 2023 | 246,766.00 |
| Dec 31, 2022 | 245,391.00 |
| Sep 30, 2022 | 230,480.00 |
| Jun 30, 2022 | 239,534.00 |
| Mar 31, 2022 | 261,384.00 |
| Sep 30, 2021 | 118,372.00 |
| Jun 30, 2021 | 154,051.00 |
| Mar 31, 2021 | 84,595.00 |
| Dec 31, 2020 | 319,608.00 |
| Sep 30, 2020 | 100,932.00 |
| Jun 30, 2020 | 285,348.00 |
| Mar 31, 2020 | 503,023.00 |
| Dec 31, 2019 | 426,115.00 |
| Sep 30, 2019 | 722,624.00 |